Managing Director of New Ventures

Redesign Health•New York, NY

About The Position

As a Managing Director of New Ventures, you will back exceptional founders at the earliest stage—often before an idea is fully formed—providing first institutional capital and an unmatched degree of strategic leverage and domain expertise through launch and beyond. This role demands generative ideation, exceptional founder judgment, and the ability to sell world-class entrepreneurs on partnering with Redesign Health. You will develop original investment theses in healthcare, identify and attract top 1% founding talent, lead co-ideation and diligence through Investment Committee, and serve as the primary interface between portfolio founders and Redesign’s platform. The core equation: Exceptional Founders × Differentiated Concepts × Redesign’s X-Factors = Power-Law Outcomes.

Requirements

Bachelor’s degree required; MBA preferred, with a record of high academic achievement.
10+ years of experience with a significant portion in venture capital, company building, or early-stage investing. Direct experience evaluating founders and making investment decisions at the pre-seed to Series A stage is strongly preferred.
Deep healthcare domain expertise with the ability to develop original investment theses across care delivery, health tech, and healthcare services.
Established network across the venture capital, healthcare operator, and startup ecosystems with a demonstrated ability to source and attract exceptional founding prospects.
Fluency in business model analysis, investment thesis development, and financial modeling.
Track record of end-to-end ownership—leading work from thesis to founder to investment decision with minimal oversight.
Deep connectivity to startup ecosystem with a proven ability to identify and attract generational founders.
Founder Quality Obsession: A refined, evolving sense of what “great” looks like in founding talent, including the ability to recognize the exceptional in non-standard backgrounds. Holds the bar even when pipeline pressure creates incentives to lower it.
Speed to Kill: The ability to say no quickly—to founders, to concepts, to your own ideas. Runs a tight pipeline where nothing lingers in an uncertain state. Comfortable cutting bait despite time invested.
Commercial Instinct: Maps every concept to a specific stakeholder’s willingness to pay, understands unit economics, and senses whether a business model can scale. Academic depth paired with commercial judgment.
Big-Swing Thinking: Aims for outsized outcomes. Generates bold concepts with conviction, even when the path is unproven. Comfortable making asymmetric bets where the upside justifies the risk.
Relationships Over Research: You spend disproportionate time with founders, VCs, operators, clinicians, and payers. You know that a few sharp primary conversations will answer questions that weeks of secondary research cannot.
Drives Results: You take initiative without over-planning, seize opportunities, and tackle challenges with urgency and enthusiasm.
Radical Honesty: You surface risks early, communicate directly even when the message is unwelcome, and maintain strong opinions loosely held. You close loops even when the answer is no.
Partnership: The founder's success is the only thing that matters. You subordinate process preferences to founder needs, adapt to their pace, and always ask "what does this founder need right now?" You are the first person every founder calls in a crisis.
Technology Innovator: All analytical and synthesis work — market sizing, landscaping, competitive mapping, secondary research — goes into AI systems. Your time is reserved for the irreplaceable: relationships, taste, judgment, primary conversations, and selling. You have built systems and workflows far more sophisticated than basic LLM usage and are constantly experimenting with new ways to compress months of work into weeks.

Nice To Haves

MBA preferred, with a record of high academic achievement.
Direct experience evaluating founders and making investment decisions at the pre-seed to Series A stage is strongly preferred.